{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:49:27Z","timestamp":1759063767301,"version":"3.40.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Chinese National 973 Program","award":["2015CB554300"],"award-info":[{"award-number":["2015CB554300"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31670172"],"award-info":[{"award-number":["31670172"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31300146"],"award-info":[{"award-number":["31300146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.antiviral.2016.12.009","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T10:49:18Z","timestamp":1482490158000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals"],"prefix":"10.1016","volume":"139","author":[{"given":"Wanyin","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2825-8148","authenticated-orcid":false,"given":"Tianyu","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.12.009_bib1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib2","doi-asserted-by":"crossref","first-page":"11979","DOI":"10.1074\/jbc.M210914200","article-title":"Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs","volume":"278","author":"Carroll","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.antiviral.2016.12.009_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver. Electronic address, e.e.e","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib4","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib6","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.3390\/v7122941","article-title":"Virologic tools for HCV drug resistance testing","volume":"7","author":"Fourati","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2016.12.009_bib7","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib8","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","article-title":"In\u00a0vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor","volume":"59","author":"Kati","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2016.12.009_bib10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib11","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2016.12.009_bib12","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib13","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a novel Pan-Genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/nsr\/nwv040","article-title":"Hepatitis C virus vaccine development: old challenges and new opportunities","volume":"2","author":"Li","year":"2015","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.antiviral.2016.12.009_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2016.12.009_bib16","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/JVI.02929-13","article-title":"A\u00a0novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate","volume":"88","author":"Lu","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.12.009_bib18","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.12.009_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.01598-08","article-title":"GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796","volume":"53","author":"McCown","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib20","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib21","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12500","article-title":"The expanding toolbox for hepatitis C virus research","volume":"23","author":"Ortega-Prieto","year":"2016","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.antiviral.2016.12.009_bib23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2016.12.009_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2016.12.009_bib25","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib26","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-014-0279-4","article-title":"Daclatasvir\u00a0+\u00a0asunaprevir: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2016.12.009_bib27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib29","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","article-title":"Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in\u00a0vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle","volume":"60","author":"Serre","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib30","doi-asserted-by":"crossref","first-page":"e113034","DOI":"10.1371\/journal.pone.0113034","article-title":"Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations","volume":"9","author":"Solund","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2016.12.009_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00535-007-2030-3","article-title":"Molecular biology of hepatitis C virus","volume":"42","author":"Suzuki","year":"2007","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.antiviral.2016.12.009_bib33","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.12.009_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.virol.2009.09.006","article-title":"A\u00a0single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles","volume":"395","author":"Tao","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.12.009_bib35","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","article-title":"Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885","volume":"57","author":"Wong","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.009_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00822942-200504040-00002","article-title":"Los alamos hepatitis C immunology database","volume":"4","author":"Yusim","year":"2005","journal-title":"Appl. Bioinforma."},{"key":"10.1016\/j.antiviral.2016.12.009_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.antiviral.2016.12.009_bib38","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1073\/pnas.0503596102","article-title":"Robust hepatitis C virus infection in\u00a0vitro","volume":"102","author":"Zhong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216306660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T12:50:18Z","timestamp":1536151818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216306660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":38,"alternative-id":["S0166354216306660"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"type":"print","value":"0166-3542"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}